Liver tumor infiltrating lymphocytes: Comparison of hepatocellular and cholangiolar carcinoma

Table 1 List of antibodies

Name	Clone	Pre-treatment	Titer	Manufacturer
CD3	PS1	10 min autoclave 120°C, citrate buffer pH 6	1:50	DAKO, Glostrup, Denmark
CD4	1F6	10 min autoclave 120°C, citrate buffer pH 9	1:10	Novocastra, Newcastle, UK
CD8	C8/144B	10 min autoclave 120°C, citrate buffer pH 6	1:100	DAKO, Glostrup, Denmark
CD20	L26	none	1:500	DAKO, Glostrup, Denmark
CD56	123C3	2 × 7 min microwave citrate buffer pH 6	1:500	Zymed, San Francisco, CA, USA
	SCLC
TIA-1	TIA-1	2 × 7 min microwave citrate buffer pH 6	1:500	Coulter Immunol., Hinleah, FL, USA

Table 2 Frequency of TIL in hepatocellular and cholangiolar carcinoma

TIL	Hepatocellular carcinoma			Cholangiolar carcinoma
	Intratumoral (/10HPF)	Peritumoral (/10HPF)	Level of significance	Intratumoral (/10HPF)	Peritumoral (/10HPF)	Level of significance
CD20	3.2 (± 9.7)	26.4 (± 49.5)	P < 0.001	0.1 (± 0.3)	11.1 (± 11.8)	P = 0.035
CD3	85.1 (± 78.2)	256.5 (± 90.5)	P < 0.001	52.6 (± 28.5)	310.4 (± 202)	P = 0.008
CD4	37.9 (± 42.5)	164.3 (± 26.4)	P < 0.001	18 (± 22.3)	223.1 (± 43.2)	P = 0.043
CD8	54.9 (± 57.9)	131.5 (± 86.8)	P ≤ 0.001	40.7 (± 30.5)	118.7 (± 35.5)	P ≤ 0.001
CD56	0.2 (± 0.6)	0.5 (± 1.1)	P = 0.058	0.4 (± 1.0)	1.9 (± 2.7)	P = 0.088
TIA-1	50.2 (± 40.5)	80 (± 64.5)	P = 0.036	41.1 (± 41.8)	72.5 (± 37.4)	P = 0.071

HPF: High power fields; TIL: Tumor infiltrating lymphocytes.